Login to Your Account

FDA rejects Spectrum bladder cancer drug

By Michael Fitzhugh
Staff Writer

Monday, November 21, 2016

Spectrum Pharmaceuticals Inc. drew an FDA complete response letter (CRL) for its experimental bladder cancer treatment, Qapzola (apaziquone), Friday, three weeks ahead of a scheduled PDUFA date.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription